Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Subsequent FDG PET/CT showed high uptake in the SPN, revealing poorly differentiated adenocarcinoma at biopsy, but with no abnormal uptake in the para-aortic nodes.
|
31652158 |
2020 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Assessment of Response to Neoadjuvant Chemoradiotherapy by 18F-FDG PET/CT in Patients With Locally Advanced Esophagogastric Junction Adenocarcinoma.
|
31714278 |
2020 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To this end, we developed a deep learning-based cognitive signature of FDG brain PET adaptable for Parkinson's disease (PD) as well as Alzheimer's disease (AD).
|
31768599 |
2020 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Breast Cancer Imaging With PET Based Radiopharmaceuticals Other Than 18F-FDG.
|
31652160 |
2020 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Utility of <sup>18</sup> F-FDG PET/CT in pre-surgical risk stratification of patients with breast cancer.
|
31587025 |
2020 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiparametric <sup>18</sup>F-FDG PET-MRI of the breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and without breast cancer?
|
31253745 |
2020 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Development and Validation of a <sup>18</sup>F-FDG PET/CT-Based Clinical Prediction Model for Estimating Malignancy in Solid Pulmonary Nodules Based on a Population With High Prevalence of Malignancy.
|
31474376 |
2020 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Abdominal Wall Granulomatous Inflammation Mimicking Malignancy on FDG PET/CT.
|
31833933 |
2020 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Metabolic information obtained through <sup>18</sup>F-flurodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) is used to evaluate malignancy by calculating the glucose uptake rate, and these parameters play important roles in determining the prognosis of non-small cell lung cancer (NSCLC).
|
31502013 |
2020 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study group comprised 132 cancer patients (116 f, 16 m; mean age 50 ± 16 years) who underwent F18-FDG PET/CT per standard clinical protocol, for staging or surveillance of cancer.
|
31650208 |
2020 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ninety-three patients with known primary tumors underwent whole-body hybrid FDG PET/MRI during the follow-up of their malignancies with the use of NCE and CE protocols.
|
31203290 |
2020 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
F-FDG PET/CT was recommended for identifying potential malignancy and showed several hypermetabolic masses in the pancreas, left testis, and right lung.
|
31693625 |
2020 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare malignancy with isolated case reports of FDG uptake on FDG PET/CT.
|
31693606 |
2020 |
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
18F-FDG PET/MRI for Rectal Cancer TNM Restaging After Preoperative Chemoradiotherapy: Initial Experience.
|
31842163 |
2020 |
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metabolic information obtained through <sup>18</sup>F-flurodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) is used to evaluate malignancy by calculating the glucose uptake rate, and these parameters play important roles in determining the prognosis of non-small cell lung cancer (NSCLC).
|
31502013 |
2020 |
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns.
|
31760467 |
2020 |
Non-Small Cell Lung Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Value of pre-therapy <sup>18</sup>F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer.
|
31728587 |
2020 |
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this retrospective monocentric study, we included 109 patients with advanced NSCLC who underwent baseline FDG PET/CT before ICI initiation between July 2013 and September 2018.
|
31754795 |
2020 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of 18F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and heck squamous cell carcinoma.
|
31705729 |
2020 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Can [<sup>18</sup>F]F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer?
|
31642963 |
2020 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the application of the radiotracers [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG), 3'-deoxy-3'- [<sup>18</sup>F]fluorothymidine ([<sup>18</sup>F]FLT), and [<sup>18</sup>F]fluoromisonidazole ([<sup>18</sup>F]FMISO) in the diagnosis and monitoring of hepatic metastasis in human colorectal cancer (CRC).
|
31330410 |
2020 |
Bacterial Endocarditis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Guidelines and/or recommendations of clinical societies have incorporated nuclear medicine tests (using both labeled leucocytes and FDG) in their suggested work-up for evaluation of infective endocarditis and in certain patients with suspected vascular graft infections.
|
31843060 |
2020 |
Bacterial Endocarditis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inclusion of abnormal 18F-FDG cardiac uptake as a major criterion at admission enabled a re-categorization of 76% (47/62) of PVE/AAPI cases initially classified as "possible" to "definite" IE.
|
30949690 |
2020 |
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Current literature suggests insufficient accuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) as single modalities for detecting residual disease after nCRT for esophageal cancer.
|
31188203 |
2020 |
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?
|
31556355 |
2020 |